All lobbying filings

TIBER CREEK GROUP

Lobbying for DAIICHI SANKYO, INC. · Global pharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Lobbying activity 2

Health Issues

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.